Skip to main content

Table 2 Correlations between GPR30 and EGFR expression and clinicopathological factors

From: GPR30 regulates the EGFR-Akt cascade and predicts lower survival in patients with ovarian cancer

Variables Expression of GPR30 p value Expression of EGFR p value
  Positive Negative   Positive Negative  
Age 54.0 ± 12.7 54.3 ± 12.2 0.49 54.3 ±11.9 53.9 ±13.5 0.84
Premenopausal 40 (60.6%) 26 (39.4%) 0.80 27 (40.9%) 39 (59.1%) 0.39
Postmenopausal 60 (60.6%) 36 (39.4%)   33 (33.3%) 63 (66.7%)  
BMI 21.5 ± 2.7 22.6 ± 4.2 0.04 21.4±3.6 22.2±2.8 0.11
Borderline malignancy 1 (10.0%) 9 (90.0%) 0.0016 0 (0%) 10 (100%) 0.012
FIGO stage I 26 (66.7%) 13 (33.3%) 0.31 13 (33.3%) 26 (66.7%) 0.77
     II 11 ( 78.6%) 3 (21.4%)   7 (50.0 %) 7 (50.0%)  
     III 47 (61.3%) 30 (38.7%)   32 (41.6%) 45 (58.4%)  
     IV 15 (68.2%) 7 (31.8%)   8 (36.4%) 14 (63.6%)  
Histology       
Borderline malignancy 1 (10.0%) 9 (90.0%) 0.0016 0 (0%) 10 (100%) 0.012
Serous adenocarcinoma 46 (75.4%) 15 (24.6%) <;0.001 24 (39.3%) 37 (60.7%) 0.42
Endometrioid adenocarcinoma 25 (83.3%) 5 (16.7%)   11 (36.7%) 19 (63.3%)  
Mucinous adenocarcinoma 14 (73.7%) 5 (26.3%)   8 (42.1%) 11 (57.9%)  
Clear cell adenocarcinoma 6 (20.7%) 23 (79.3%)   14 (48.3%) 15 (51.7%)  
Others 8 (61.5%) 5 (38.5%)   3 (23.1%) 10 (76.9%)  
Recurrence    0.30    0.31
≤ 6M 13 (68.4%) 6 (31.6%)   9 (47.4%) 10 (52.6%)  
> 6M 43 (67.2%) 21 (32.8%)   20 (31.3%) 44 (68.7%)  
No recurrence 44 (55.7%) 35 (44.3%)   31 (39.2%) 48 (60.8%)  
5-year survival    0.56    0.86
Alive 63 (61.8%) 39 (38.2%)   35 (34.3%) 67 (65.7%)  
Dead 37 (61.7%) 23 (38.3%)   25 (41.7%) 35 (58.3%)